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   SUMMARY 
1 SUMMARY 
The critical role of the activation of signal transducer and activator of transcription 3 
(STAT3) in the growth and survival of human tumor cells was was one of the subjects 
of this thesis. It was found that the stable incorporation of v-Src into MCF10A cells, a 
human immortalized breast epithelial cell line, induced constitutive phosphorylation of 
STAT3 in these cells. MCF10A-v-Src cells displayed growth factor independence for 
proliferation and survival, and anchorage independence. However, these cells did not 
form tumors in nude mice, indicating that they were not fully transformed. 
Furthermore, inhibition of activated STAT3 in 293 cells decreased growth and 
induced apoptosis in these cells. The same results were obtained in 293 cells stably 
transfected with tetracycline-inducible dominant negative (DN) STAT3, and in 293 
cells transiently expressing STAT3 RNAi. 
Since STAT3 promises to be a good target for cancer treatment, it was attempted to 
develop inhibitors through rational design. Within STAT3, the SH2-domain was 
chosen as being the best target site. One limitation of this site turned out to be its 
similarity to family members in this region, and even to other SH2-domain containing 
proteins, such as Src, all of which present a highly conserved pocket to bind 
phosphotyrosines. A medium-throughput assay to measure STAT3 dimerization in 
vitro was established to determine the affinity of compounds to the SH2-domain of 
STAT3. Peptides of different length derived from the phosphotyrosine-containing 
motif of STAT3 (AAPY*LKTKF) were tested in the assay. Y*L was found to be the 
minimal sequence to block dimerization, and out of the tested peptides, PY*LKT had 
the highest affinity. This was consistent with the observations made on the crystal 
structure of STAT3, which indicated that besides the phosphotyrosine-binding site, 
position + 1 and + 3 contributed most importantly to binding. The relevance of 
position + 1 was further confirmed by substitution of Leu+ 1 by Ala in the peptide 
Y*LKT, which decreased the affinity more than ten times. Finally, one non-peptidic 
small molecule inhibitor identified by virtual ligand screening (VLS) proved to be a 
STAT3 dimerization inhibitor in vitro. This is the first small molecule inhibitor of 
STAT3 identified so far, and might serve to study structure activity relationships 
(SAR) to optimize the structure and find more potent and bioavailable compounds. 
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2 INTRODUCTION 
2.1 The Signal Transducers and Activators of Transcription 
(STAT) family 
 
Signal Transducers and Activators of Transcription (STATs) are a family of proteins 
present latently in the cell, which mediate signals downstream of cytokine and growth 
factor receptors. STATs were first identified in the 1990s as DNA-binding proteins 
that attached to the promoters of interferon-inducible genes (Shuai et al. 1993). Since 
then, seven different family members have been cloned and characterized (STAT1 to 
4, STAT5A and B, and STAT6), all of which are encoded by different genes. These 
proteins are considered to have a dual function, acting as signal transducers 
(transmitting signals from the membrane to the nucleus), and as transcription factors 
(activating the expression of genes once they bind to their promoters).  
Structurally, STATs have several common domains (Fig.1):  
• a N-terminal domain involved in the oligomerization of dimers 
• a 4-helix bundle 
• a β-barrel domain and a connector, involved in DNA-binding 
• a Src-homology 2 (SH2) domain that mediates interaction with phosphorylated 
receptors and dimerization 
• a phosphotyrosine containing sequence involved in dimerization 
• a C-terminal transactivation domain, which can interact with the transcriptional 
machinery, transcriptional coactivators, and other regulators of gene 
expression 
 
Fig.1. Domain structure of STAT3. 
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2.2 Activation of STATs 
 
2.2.1 TYROSINE PHOSPHORYLATION 
 
The binding of cytokines to their receptors (Fig.2) induces conformational changes in 
the receptor, along with their aggregation. This enables the kinases bound to their 
intracellular domains, the Janus family of kinases (JAK), to phosphorylate each other 
and become activated. The JAK family has four members: JAK1, JAK2, JAK3, and 
Tyk2, all of which show significant homology. They constitutively bind to the 
cytoplasmic tails of a variety of cytokine and hormone receptors, and, when 
activated, these kinases phosphorylate specific tyrosine sequences in the receptors. 
The phosphorylated receptors are recognized by the SH2-domains of STATs. This 
enables their localization to the membrane. In close proximity to the JAK kinases, 
STATs can then be phosphorylated by these enzymes. In the case of growth factors, 
such as EGF and PDGF, the intrinsic tyrosine kinase activity of the receptors may 
directly phosphorylate STATs. Some groups have reported dimerization of STAT 
proteins prior to phosphorylation. However, these dimers do not translocate to the 
nucleus, and are also not capable of binding to the DNA and activate gene 
transcription (Haan et al. 2000;Braunstein et al. 2003;Schroder et al. 2004). This 
finding could invalidate the current model of STAT activation and support a new 
model, according to which STATs are already dimerized prior to phosphorylation. 
Haan et al. (1999) observed complex formation of purified STAT3 SH2-domain, and, 
using fluorescence resonance energy transfer (FRET) in living cells, Kretzschmar et 
al. (2004) found that STAT3 dimers exist in the absence of tyrosine phosphorylation. 
So, while the direct recruitment of STAT molecules to activated receptors might be 
the most common, and conceptually certainly the simplest mechanism of activation, 
the general model of phosphotyrosine-dependent recruitment might not always apply.  
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Phosphorylation of STATs activates them by stabilizing the dimerization of two STAT 
monomers through reciprocal phosphotyrosine-SH2 interactions. STAT dimers bind 
to each other through the respective SH2-domains of each monomer. It is thought 
that dimerization is favored to attachment to the receptor, since the former interaction 
involves the binding of two different phosphotyrosine and SH2-domains, while the 
latter takes place through only a single SH2-domain. A nuclear localization sequence 
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is exposed in STATs upon dimerization. Therefore, upon activation, the monomers 
detach from the receptors, and the dimers translocate to the nucleus, where they 
bind to specific DNA-response elements in the promoters of target genes (Seidel et 
al. 1995). Each family member recognizes a slightly different palindromic sequence, 
and can thereby induce a unique gene expression profile.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2. Mechanisms of STAT3 activation. Classical 
pathway: downstream of cytokine or growth factor 
signaling, and alternative pathway: involving soluble 
tyrosine kinases. 
 
 
 
 
 
 
 
2.2.2 SERINE PHOSPHORYLATION  
 
The C-terminal region of STATs contains the transactivation domain, which is 
required for activation of transcription. Proteins such as the histone acetyl-transferase 
p300/CREB-binding protein interact with the C-terminal domain of these transcription 
factors. STAT1 and STAT3, but it has also been reported that STAT4, STAT5A, 
STAT5B, and STAT6, can be further phosporylated at a Ser at the C-terminus (Ser727 
in STAT1, Ser727 in STAT3, Ser721 in STAT4, Ser725 and Ser779 in STAT5A, Ser730 in 
STAT5B, and Ser756 in STAT6). This serine phosphorylation enhances and 
maximizes their transcriptional activity, but is by itself neither sufficient nor required 
for their activities. The transcriptional enhancement involves mechanisms that are not 
fully understood, but may include interactions between STAT coactivator proteins 
 5
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involved in gene activation. Consequently, both tyrosine and serine phosphorylation 
are necessary for full activation of STATs, indicating their modulation by different 
pathways in the cell. STATs could therefore be considered convergence points of 
different cascades, involving both tyrosine and serine kinases. 
However, unlike the better characterized events in STAT activation by tyrosine 
phosphorylation, the regulation of STATs by serine phosphorylation is less well 
understood. Mitogen-activated protein kinases (MAPK), including extracellular signal 
regulated kinases (ERK), c-Jun N-terminal kinase (JNK), and p38MAPK participate in 
the serine phosphorylation of STAT1 and STAT3 (Chung et al. 1997;David et al. 
1995;Gollob et al. 1999;Kuroki and O'Flaherty 1999;Lim and Cao 1999;Ng and 
Cantrell 1997;Turkson et al. 1999). Furthermore, protein kinase C (PKC) plays a role 
in serine phosphorylation of STATs (Jain et al. 1999). Also implicated in the serine 
phosphorylation are two undefined serine kinases: an H7-sensitive serine kinase, 
and MAPK kinase (MKK)-dependent/ERK-independent serine kinases (Boulton et al. 
1995;Ceresa et al. 1997;van Puijenbroek et al. 1999;Chung et al. 1997). Direct 
phosphorylation of STAT3 and STAT1 in vitro by ERKs, p38 and JNK provides 
evidence that members of the MAPK family can induce STAT serine phosphorylation 
and regulate their activity physiologically (Chung et al. 1997;Turkson et al. 1999). 
Furthermore, the site of serine phosphorylation in both STAT3 and STAT1, Pro-Met-
Ser-Pro complies with the MAPK consensus sequence, Pro-X-Ser/(Thr)-Pro 
(Gonzalez et al. 1991;Schaeffer and Weber 1999). Presumably, the relative 
contribution of each of these serine kinases to STAT signaling in the cell depends on 
a variety of factors, including cell-type specific expression of the serine kinases, and 
their interactions with individual STAT members. 
 
2.3 Specificity of the JAK-STAT pathway 
 
The specificity of the JAK-STAT cascade is not driven by the kinases, as is usually 
the case with other cellular enzymes, but by the recruitment site for STATs in the 
receptor. The phosphotyrosine and its surrounding sequence in the receptor can only 
bind proteins with a complementary SH2-domain. For example, the IFNγ (resp IL6, 
resp erythropoetin) receptor activates mainly STAT1 (resp STAT3, resp STAT5), 
while both first receptors activate JAK1 and JAK2, and the third only JAK2. However, 
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the EGF receptor, which also binds JAK1 and JAK2, can activate STAT1, STAT3, 
and STAT5. Like other phosphotyrosine/SH2-domain interactions that have been 
characterized in other proteins, e.g. Src kinase, this binding is of high affinity and is 
highly specific. Hence, the specificity comes from the receptors themselves, and is 
independent of the kinases involved.  
The events described above lead to the activation of STATs very rapidly. Active 
STATs can be detected in the nucleus only five to fifteen minutes after the addition of 
cytokines (e.g. IFNα, IFNγ, PDGF, LIF, EGF) in tissue culture (Raz et al. 1994). This 
also demonstrates the direct role of these transcription factors in the cytokine and 
growth factor responses.  
 
2.4 STATs and gene activation 
 
Once phosphorylated, STATs dimerize and translocate to the nucleus, where they 
bind to the DNA and modulate gene expression. Each STAT family member activates 
different genes. For example, STAT3 is known to activate cyclin D1, bcl-xl, 
p21WAF1/CIP1, and c-myc, whereas STAT5 activates Pim1 and oncostatin-M. Each 
STAT binds to a specific palindromic sequence in the DNA, and activates only the 
genes that contain this sequence in their promoters (Seidel et al. 1995). Studying the 
binding elements in the promoters of cytokine-responsive genes, it has been found 
that STATs bind to strongly conserved sequences, with the consensus TT(N)4-6AA, 
where N represents any nucleotide (Seidel et al. 1995). Screening of oligonucleotides 
to find the optimum binding sites for STAT 1, 3, and 4 resulted in the recovery of the 
consensus oligonucleotide sequence, TTCC(C or G)GGAA (or generically TT(N)5AA) 
(Horvath et al. 1995;Xu et al. 1996). Only STAT6, which binds optimally to TT(N)6AA 
sequences, prefers different optimal binding sites (Seidel et al. 1995;Mikita et al. 
1996;Schindler et al. 1995). However, the natural sites present in the promoters of 
genes that are regulated in response to particular cytokines show clear preferential 
binding affinities for a particular STAT or a sopecific set of STATs (Horvath et al. 
1995;Schindler and Darnell, Jr. 1995;Mikita et al. 1996;Xu et al. 1996;Schindler et al. 
1995). Interactions between all the different proteins bound on a specific promoter 
could influence the DNA-binding stablility of these transcription factors, and this 
would explain the selective gene activation by each STAT in vivo. 
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2.5 Regulation of the JAK-STAT pathway: the Suppressors Of 
Cytokine Signaling (SOCS) and the Protein Inhibitors of 
Activated STATs (PIAS) 
 
The SOCS protein family are negative regulators that bind to the receptors and JAK-
family kinases to block STAT activation. Another family of negative regulators are the 
PIAS, which interact directly with STAT proteins and block their DNA-binding activity. 
The importance of these physiological negative regulators in cancer is illustrated by 
the observation that one SOCS family member, SOCS1, is silenced by DNA 
methylation in multiple myeloma, AML and hepatocellular carcinoma (Galm et al. 
2003;Coppo et al. 2003;Yoshikawa et al. 2001). Furthermore, loss of PIAS3 is 
associated with T-cell lymphoma (Zhang et al. 2002a). The inactivation of these two 
negative regulators might foster the persistent activation of STATs in these tumors. 
Protein tyrosine phosphatases, such as SH2-containing phosphatases SHP1 and 
SHP2, are able to negatively regulate STAT signaling by tyrosine dephosphorylation 
of several components in the pathway. Although all of these STAT regulating proteins 
are potential candidates for therapeutic development, they are known to regulate 
other proteins, so that mimics of their function might not be entirely specific to STAT 
signaling. Additionally, it would be necessary to find activators of these proteins, 
which is more difficult than finding inhibitors. 
 
2.6 The physiological functions of STATs 
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STATs regulate cellular processes, including proliferation, differentiation, survival, 
angiogenesis, haematopoiesis and inflammation (Darnell, Jr. 2002). Each family 
member has specific functions, which span a wide range of often antagonic activities: 
from regulation of antiviral host response (Chang et al. 2002;Improta and Pine 1997) 
to the regulation of T-cell development (Kaplan et al. 1996;Kaplan and Grusby 
1998;Kuo and Leiden 1999;Mohrs et al. 2003;Moriggl et al. 1999); from stimulation of 
proliferation and survival (e.g. STAT3 stimulates growth, and is essential for 
transformation by certain oncogenic tyrosine kinases) to apoptosis in others (e.g. 
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STAT1 inhibits proliferation and activates apoptosis (Fukada et al. 1996,Amin et al. 
2004;Ning et al. 2001;Zhang et al. 2002b;Stephanou and Latchman 2003). 
The contribution of each STAT to the control of normal cellular processes has been 
elucidated based on studies of gene knockouts in mice. The family members 
presenting a lethal phenotype have been studied in tissue-specific conditional 
knockouts. Homozygous deletion of STAT1 in mice results in deficiencies in their 
ability to respond to interferons, and these mice become vulnerable to infections from 
bacterial and viral pathogens (Durbin et al. 1996;Meraz et al. 1996). Targeted 
disruption of STAT4 in mice (Kaplan et al. 1996;Thierfelder et al. 1996) (resp STAT6 
(Shimoda et al. 1996;Takeda et al. 1996)) causes impairments in IL-12 (resp IL-4) 
induced proliferation of activated T lymphocytes. 
Despite their almost identical names, STAT5A and STAT5B have independent genes 
coded by different chromosomes, and their respective knockouts exhibit different 
phenotypes: In the case of STAT5A the mice present deficient mammary gland 
development and lactation during pregnancy (Liu et al. 1997), while STAT5B 
knockouts display sexually dimorphic patterns of liver gene expression (Udy et al. 
1997). Female STAT5A and B double-knockouts are infertile, and present 
deficiencies in their immune system (Teglund et al. 1998). 
In the case of STAT2 (Kimura et al. 1996) and STAT3 (Takeda et al. 1997), 
homozygous deletion of each gene is embryonically lethal, indicating an essential 
role in normal embryonic development. The Cre-Lox recombination system has been 
used for the development of tissue-specific STAT3 knockouts, in order to circumvent 
their mortality at day 6.5 to 7 of embryonic development. This has lead to the 
discovery of the relevance of STAT3 signaling in wound healing (Sano et al. 1999), 
and in IL-6 dependent survival of T lymphocytes (Takeda et al. 1998). 
 
2.7 Dominant negative forms of STATs 
 
Naturally occurring splice variants of STATs, such as STAT1β and STAT3β, lack the 
C-terminal transactivation domain and the serine phosphorylation site. Interestingly, 
they can often block the function of the full-length proteins (also named α forms) in a 
dominant negative manner. The physiological role of these isoforms is not completely 
understood: they are known to be negative regulators of STAT activity in certain 
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tissues and under specific circumstances, and they might also perform additional and 
different activities from the α forms. The β forms conserve the DNA-binding capacity, 
but do not activate genes, which is a logical consequence of their lack of 
transactivation domain. In biological assays STATβ isoforms are often used as 
inhibitory tool. 
 
2.8 Constitutively activated mutants of STATs 
 
Artificial mutations of STATs, which render them constitutively active by various 
mechanisms, demonstrate that persistent activation of STAT3 and STAT5 is 
sufficient to induce at least some aspects of cell transformation. A constitutively 
activated STAT3 molecule, STAT3C has been genetically engineered to enable 
dimerization in the absence of tyrosine phosphorylation. As a result of this enforced 
dimerization, STAT3C homodimers migrate to the nucleus, bind to STAT3 response 
elements in promoters and induce gene expression. Moreover, mouse fibroblast 
expressing STAT3C form colonies in soft agar and induce tumors in nude mice 
(Bromberg et al. 1999). Thus, constitutive activation of STAT3 DNA-binding leads to 
induction of a STAT3 dependent genetic program that is sufficient to recapitulate 
some hallmarks of cell transformation in the absence of other signaling pathways that 
might be activated by TKs. This finding provides further evidence of the causal role of 
constitutively activated STAT3 signaling in oncogenesis, as opposed to being merely 
a side effect of TK activity, which also leads to the phosphorylation of many other 
proteins in the cell. The identification of other STAT3 regulated genes will be 
important to further define the underlying mechanisms of neoplastic transfomation 
resulting from constitutive STAT3 signaling.  
Expression of constitutively activated STAT5 in an IL-3 dependent mouse pre-B cell 
line, induces growth factor independent proliferation (Onishi et al. 1998). This 
suggests that STAT5 may also contribute to oncogenesis by promoting cell cycle 
progression and/or survival. 
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Fig.3. STAT3 variants. STAT3α and β are two naturally occurring isoforms of STAT3, the former 
being the active variant, and the latter a dominant negative. STAT3C is an artificial mutant with 
constitutive activity.  
 
2.9 STAT3 in disease 
 
Based on the diverse activities of STATs and on the phenotypes of the deficient 
mice, it is not surprising that these proteins have been found deregulated in many 
different kinds of diseases. In particular, STAT3 is constitutively active in 
inflammatory diseases, such as rheumatoid arthritis (Krause et al. 2002;Liu and Pope 
2003), Crohn's disease (Atreya et al. 2000;Lovato et al. 2003), and atherosclerosis 
(Niculescu and Rus 1999), and also in many cancers. These include solid tumors: 
head and neck carcinoma (Song and Grandis 2000), breast cancer (Lin et al. 
2002;Berclaz et al. 2001), ovarian cancer (Huang et al. 2000), prostate cancer 
(Barton et al. 2004;Campbell et al. 2001;Dhir et al. 2002;Gao et al. 2001;Mora et al. 
2002), cervical cancer (Page et al. 2000), melanoma (Niu et al. 2002), and renal 
carcinoma (Horiguchi et al. 2002), as well as leukemias (Lin et al. 2000): Acute 
myeloid leukemia (Schuringa et al. 2000;Towatari and Iida 1998;Xia et al. 1998), 
acute promyelocytic leukemia (Dong et al. 2003), Hodgkin lymphoma (Kube et al. 
2001), anaplastic lymphoma kinase-positiveT/Null-cell lymphoma (Zhang et al. 
2002a), adult T-cell leukemia/lymphoma (Takemoto et al. 1997), CML (Coppo et al. 
2003) and ALL (Spiekermann et al. 2001;Schuringa et al. 2000;Benekli et al. 2002). 
Persistent STAT3 signaling in tumor cells induces tumor angiogenesis and 
suppresses anti-tumor immune responses, which seems to further boost tumor 
progression (Cheng et al. 2003;Wang et al. 2004). Additionally, it appears that some 
tumor cells become dependent on constitutive STAT3 activation and are more 
sensitive to STAT3 inhibitors than normal cells. 
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2.10 STAT3 as an oncogene 
 
STAT3 in particular can be considered an oncogene, since the constitutively 
activated mutant, STAT3C, is capable of inducing tumors in nude mice (Bromberg et 
al. 1999). However, since no STAT3 mutation has been detected in human tumors so 
far, this statement could be challenged. Oncogenes are defined as mutated forms of 
proto-oncogenes, which are genes whose products are involved in growth 
stimulation. The mutations can affect the genes promoter and cause protein 
overexpression, but they can also affect the coding region and generate a 
hyperactivated mutant. As yet, none of these have been reported for STAT3. Rather, 
its activation in malignancies seems to occur downstream of hyperactivated tyrosine 
kinases and other types of oncogenes. However, STAT3 and STAT5 activate 
cyclinD1, c-Myc, and bcl-xl, and it is generally accepted in the field that STAT3 
promotes cell growth and therefore oncogenic processes. Furthermore, as noted 
above, a number of different groups have reported constitutive activation of this 
protein in various tumor types. Hence, even though not being a bona fide oncogene, 
but because of its direct activation by other oncogenic factors and its role in growth 
stimulation, STAT3 can still be considered an appropriate target for cancer treatment. 
 
2.11 STAT3 as a target for cancer treatment 
 
Tyrosine kinases are among the most frequently activated oncogenic proteins in 
cancer cells. Therefore it is not surprising that persistent activation of STAT signaling 
has been detected in an increasing number of human cancers. STATs often become 
consistently activated when one or more upstream tyrosine kinases become 
overactive. Although cancer is characterized by an accumulation of genetic mutations 
at the DNA level, and oncogenes play an important role in its pathogenesis, the best 
molecular targets for cancer therapy are not necessarily genetically altered 
themselves. It has been found that some oncogenic signaling pathways converge at 
a limited set of nuclear transcription factors, including STAT3. These transcription 
factors are the final switches that activate gene expression patterns leading to 
malignancy. It is therefore logical to choose these proteins as anticancer targets, 
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since targeting a single transcription factor can block the effects of a multitude of 
upstream genetic aberrations leading to cancer.  
A gene-therapy vector that was designed to inhibit STAT3 signaling in a mouse 
model of murine melanoma has provided proof of concept that human SAT3 is a valid 
target for cancer therapy (Niu et al. 1999). In this study, the expression of a 
dominant-negative form of STAT3 induced massive apoptosis in mouse melanomas. 
An unexpected side effect of targeting STAT3 was the accompanying bystander 
effect: adjacent tumor cells also underwent apoptosis without having undergone gene 
therapy. These studies were performed in immunocompetent mice using a syngeneic 
mouse-melanoma cell line. Therefore, this potent bystander effect might involve the 
immunosuppressive activity of STAT3 (Cheng et al. 2003;Wang et al. 2004). 
However, it might also reflect the importance of STAT3 signaling for angiogenesis, or 
for the release of soluble factors capable of inducing apoptosis. Given the similarities 
between STAT3 and STAT5, it is worth investigating whether gene therapy of STAT5 
dependent tumors triggers a similar bystander effect.  
Finally, tissue-specific ablation of STAT3 has shown that non-oncogenic cells lacking 
STAT3 proliferate and survive well in vitro and in vivo (Akira 2000). Furthermore, 
inhibition of STAT3 in mouse fibroblasts does not have deleterious effects in normal 
cell growth (Niu et al. 1999;Turkson et al. 1998). The selective response to STAT3 
inhibitors in tumor versus normal cells might reflect that tumor cell growth and 
survival irreversibly depend on high levels of activated STAT3, whereas normal cells 
might be able to withstand lower levels or use alternative pathways. This is an ideal 
property of a therapeutic target, since it could imply that STAT3 inhibitors should not 
affect normal cells.  
A specific inhibitor for STAT3 could therefore be very useful for the treatment of 
cancer. STAT5 is also activated in many tumors (Calo et al. 2003) and STAT6 has 
immunosuppressive activity (Ostrand-Rosenberg et al. 2004). Hence, they are also 
potentially good drug targets for tumor therapy. Additionally, STAT1 is persistently 
activated in acute leukemias (Spiekermann et al. 2001;Calo et al. 2003;Gouilleux-
Gruart et al. 1997). However, STAT1 activation in cancer is probably a side effect of 
a hyperstimulated cytokine or growth factor signaling pathway that activates different 
proteins simultaneously. Currently, this STAT family member is considered to have 
tumor suppressive activity, inhibitig proliferation, and activating apoptosis (Bromberg 
and Darnell, Jr. 2000). Hence it should not be a target for cancer treatment. Overall, 
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STAT3 seems to be the most promising candidate of the family, not only due to its 
activation in many tumors, but also because of its immunosuppressive activity 
(Cheng et al. 2003;Wang et al. 2004). Its inhibition could slow down the proliferation 
of oncogenic cells, as well as stimulate antitumor immunity, which should therefore 
result in a potent reduction of tumor growth. 
 
2.12 Development of STAT3 inhibitors 
 
STAT molecules could be inhibited through different mechanisms. It is conceivable to 
target upstream activators of STAT3, in particular the kinases that phosphorylate 
STATs. This is very useful in the treatment of CML, because in most cases the 
causative agent of this malignancy is a translocation between chromosomes 14 and 
22 that generates the Philadelphia chromosome. This results in the expression of a 
fusion protein, Bcr-Abl, which is a hyperactivated mutant of Abl. The recent approval 
of a Bcr-Abl tyrosine kinase inhibitor, STI-571, was a major advance in the treatment 
of CML. In the case of STAT3, inhibition of its phosphorylation through a blockade at 
the kinase level has some important limitations, most importantly, the fact that many 
different kinases can activate STAT3: Hence, it should be expected that only in 
specific cases inhibition of only one kinase could lead to disappearance of 
phosphorylated STAT3. Additionally, it would be necessary to develop many different 
kinase inhibitors to treat all the possible disorders that might present STAT3 
activation, since in each case, phosphorylation can be due to other kinases. Finally, 
kinases do not only phosphorylate one substrate, but they usually many different, 
and their inhibition could have undesirable consequences due to the blockage of 
other pathways. Therefore, targeting the kinase or other upstream regulators, such 
as the cytokine receptors, does not seem to be an optimal way to disrupt STAT3 
activation.  
Within STAT3, the different functional domains are well characterized, and its 
structure has been characterized by x-ray crystallography (Becker et al. 1998) 
(Fig.4). This important input allows the rational design of inhibitors. In order to choose 
the best target site in STAT3, both the structure-function aspects and the physico-
chemical properties are relevant. The candidate inhibition sites are the DNA-binding 
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domain, the dimerization domain, the nuclear localization site, and the transactivation 
domain.  
 
 
Fig.4. Ribbon diagram of the STAT3 homodimer 
bound to the DNA: N-terminal-helix bundle (red), β-
barrel (blue), connector (green), SH2-domain (violet), 
phosphotyrosine-containing (turquoise), DNA (gold). 
 
 
 
 
 
There are many different ways to search for a candidate drug once a specific target 
site in a molecule is chosen. Typically, drug companies screen more or less randomly 
created compound libraries for the desired inhibitory activity. Hundreds of thousands 
of molecules are tested with high-throughput screening procedures in the hope of 
detecting the desired activity. A soluble and active compound becomes a lead 
compound when it has repeatedly shown specific inhibition of the target, and is then 
further modified and tested in order to find more potent candidates. With the recent 
discovery of the structure of many molecules, due to the high-resolution obtained by 
x-ray crystallography and nuclear magnetic resonance spectroscopy, another 
approach to drug screening has been attempted. In this approach, known as rational 
drug design, the available structural information is used to select compounds to be 
tested. Additionally, in the case of STATs, since they all have a similarity of 50 to 
60%, one can predict with a high degree of confidence the yet unsolved structure of 
the other family members. Using structure analysis software, one can not only view 
these proteins in three dimensions, but also select an appropriate target site more 
easily based upon specific information about the structure and electrostatics of the 
protein to be targeted. This makes it possible to define a pharmacophore even before 
active compounds are found, and to select promising compounds to be tested. 
In order for a domain to be a good target site for inhibitor development, it has to fulfil 
certain requirements, namely:  
1. Being part of the site involved in the activity of the protein, or having the 
capacity to influence the conformation of the active site.  
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2. The domain in particular needs to present a pocket in order to enable 
attachment of small molecules. Shallow surfaces generally do not allow for 
strong binding of inhibitors. 
3. For intracellular targets, such as STAT3, the site cannot be too polar, so that 
potential binders have a certain lipophylicity allowing them to pass the cellular 
membrane.  
4. The target site needs to present substantial structural differences from the 
other proteins in the cell in order to obtain specific inhibitors. 
The nuclear localization signal could also be considered for inhibition, however the 
implicated sequence has not been described for STAT3. There have been reports 
showing the relevance of an arginine/lysine rich sequence in the nuclear import of 
STAT1 and 2 by importin alpha (Melen et al. 2001;Fagerlund et al. 2002;McBride et 
al. 2002), and a nuclear export sequence has also been characterized for STAT1 
(McBride et al. 2000). However, both are located in the DNA-binding domain, and 
potential inhibitors would also inhibit DNA-binding. If the nuclear localization signal of 
STAT3 is also in the same region, studying the DNA-binding domain should also help 
to find inhibitors of nuclear localization. Another study using N-terminal mutants of 
several STAT proteins, has implicated the N-terminal domain in nuclear import 
(Strehlow and Schindler 1998). Hence, with the information published so far, it is not 
easy to carry out rational design of STAT3 nuclear localization inhibitors. 
Another option to inhibit STAT3 activity is to target the DNA-binding domain, which is 
essential for the activation of gene transcription. Targeting the DNA-binding domain 
has the benefit that the inhibitors can bind to the dimeric or monomeric form of 
STAT3, and tumors predominantly have large amounts of the activated dimer. 
Nonetheless, a strong SH2 inhibitor, which would only bind the monomeric form, and 
a strong DNA-binding inhibitor, which could target both the monomer and the dimer, 
should only differ in the kinetic of inhibition: when targeting the dimer, the effects 
could be expected to take place earlier, while in the case of the monomer, it might be 
necessary to wait for dephosphorylation of the activated STAT3 molecules for 
complete inhibition. 
The SH2-domain of STAT proteins serves for the recruitment of non-phosphorylated 
STATs to specific receptors, and is also required for their dimerization. Only 
phosphorylated and dimerized STATs translocate to the nucleus, bind to the DNA, 
and activate gene transcription. Blocking the SH2-domain of STATs, these proteins 
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cannot get phosphorylated, and can also not bind to other STAT monomers. 
Inhibition of the SH2-domain targets two different and essential events in STAT 
activation: phosphorylation and dimerization. Therefore, in respect to the first feature 
required for a good target site, this domain is a promising candidate for the inhibition 
of STAT3 activity. In 2001 it was found that STAT3 activity could be inhibited using 
STAT3 phosphopeptides that bound to its SH2-domain (Turkson et al. 2001). This 
group reported XY*L as a minimal peptide to disrupt STAT3 dimers, and further 
showed that inhibition with a cell permeable PY*LKTK peptide suppressed 
transformation by the Src oncoprotein (Turkson et al. 2001). In 2004, the same 
laboratory reported peptidomimetics with increased affinity that inhibited cell growth 
and induced apoptosis, further confirming that SH2-domain inhibitors could be 
efficient. 
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3 SPECIFIC AIMS 
 
The aim of the this thesis was two-fold, namely: 
1. The study of the role of STAT3 in human tumor development.  
As noted in the introduction, oncogenic properties have been ascribed to STAT3, 
a fact which has been well established in rodent cells. However, it is still not 
settled whether activated STAT3 can transform human cells. The sufficient and 
essential role of STAT3 in human tumor development was addressed in the 
present thesis by way of the following questions: 
• Does constitutive phosphorylation of STAT3 lead to transformation of human 
cells? Do such cells generate tumors in vivo? 
• Is it possible to establish an inducible knockdown system for STAT3? Does 
such inhibition of STAT3 lead to growth arrest and apoptosis of human cancer 
cells? 
• Does inducible STAT3 inhibition suffice to cause tumor regression of human 
xenografts in mice? 
2. Identification of drug-like STAT3 inhibitor compounds by rational drug design. 
It was mentioned that inhibition of STAT3 has been proposed for the treatment of 
cancer, and no drug-like STAT3 inhibitor compound has been described so far. 
The identification of such molecules, by means of rational drug design, using the 
functional and structural information available, required addressing the following 
questions: 
• What can be a promising target site in STAT3? Is the SH2-domain a good 
target site in STAT3? Which amino acids are important for the interactions 
taking place in a STAT3 dimer?  
• Is it possible to use the information in STAT3 crystal structure to develop SH2-
domain inhibitors through rational design? 
• Can the inhibitory compounds be validated by STAT3 specific assays? 
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4 MATERIALS AND METHODS 
 
4.1 Chemicals, enzymes, and solutions 
 
All commonly used chemicals were purchased from Merck, Sigma Aldrich, Qiagen, 
Amersham-Biosciences, Bio-Rad or LaRoche Diagnostics. Peptides were 
synthesized at PolyPeptide Laboratories or at BIOTREND Chemikalien GmbH. 
Radiochemicals were purchased from Amersham Biosciences. 
All solutions were prepared in double deionized water. To prepare sterile solutions, 
this water was previously autoclaved. 
 
4.2 Antibodies 
 
Penta-His Antibody, BSA-free Mouse monoclonal antibody recognizing 6xHis tags 
(Qiagen) 
Anti-FLAG M2  Mouse monoclonal antibody recognizing the Flag 
peptide sequence DYKDDDDK (Sigma Aldrich) 
STAT1 p84/p91 (E23) Rabbit polyclonal antibody recognizing the           
C-terminal sequence of STAT1 (Santa Cruz) 
STAT3 (C-20) Rabbit polyclonal antibody recognizing the            
C-terminal sequence of STAT3 (Santa Cruz) 
STAT3 (H-190) Rabbit polyclonal antibody raised against a 
recombinant protein mapping at amino acids 50 to 
240 of STAT3 (Santa Cruz) 
STAT3 (F-2) Mouse monoclonal antibody raised against a 
recombinant protein mapping at amino acids 50 to 
240 of STAT3 (Santa Cruz) 
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STAT3 Rabbit polyclonal antibody recognizing a sequence 
of 39 amino acids at the C-terminus of STAT3 
(Active Motif) 
Phospho-STAT3 Rabbit polyclonal antibody recognizing Tyr705 
phosphorylated STAT3 (Cell Signaling) 
Src Mouse monoclonal antibody recognizing the amino 
acids 82 to 169 of pp60Src (Upstate) 
HRP-conjugated anti-rabbit  Peroxidase-conjugated AffiniPure F(ab)2 fragment 
of donkey anti-rabbit IgG (Jackson 
Immunoresearch)  
HRP-conjugated anti-mouse Peroxidase-conjugated AffiniPure F(ab)2 fragment 
of donkey anti-mouse IgG (Jackson 
Immunoresearch) 
 
4.3 Plasmids and baculoviruses 
4.3.1 Plasmids 
 
pM/v-src: pp60-v-src eukaryotic expression vector with the Maloney virus 
promoter and ampicillin resistance (Kmiecik and Shalloway 1987); kind gift of James 
Turkson  
 
PEF/pGK/puropA eukaryotic expression vector for puromycin-resistance under 
the control of pGK promoter, and with ampicillin resistance (Huang et al. 1997); kind 
gift of Matthias Grell 
 
PSG5 humanSTAT3ß eukaryotic constitutive expression vector of STAT3ß 
under the control of SV40-virus promoter, and with ampicillin resistance 
(Caldenhoven et al. 1996); kind gift of James Turkson 
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pDEST10 donor plasmid for the generation of recombinant baculoviruses 
expressing full length STAT3: contains a mini-Tn7 element used for the generation of 
recombinant bacmids in E. coli DH10Bac, with gentamycin and ampicillin resistance 
(Invitrogen)  
 
 
PIND/V5-His-TOPO eukaryotic ponasterone-inducible expression vector, with 
neomycin and ampicillin resistance (Invitrogen) 
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pVgRXR eukaryotic constitutive expression vector of ponasterone receptor, with 
zeocin resistance (Invitrogen) 
 
 
pFRTLacZeo a plasmid containing a Flip-recombination target (FRT) site, and the 
β-galactosidase reporter gene, with zeocin and ampicillin resistance (Invitrogen). This 
vector serves the integration of genes, by Flp recombinase-mediated DNA 
recombination with other plasmids that also have FRT sites (e.g. 
pcDNA5FRT/FRT/TO). pFRTLacZeo transfected cells can be tested for protein 
expression with the β-galactosidase reporter. This assures the integration of genes 
into the genome at a transcriptionally active locus.  
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pcDNA5FRT/FRT/TO eukaryotic tetracycline-inducible expression vector, with 
hygromycin and ampicillin resistance (Invitrogen) 
 
 
pcDNA6/TR eukaryotic constitutive expression vector of the tetracycline repressor, 
with blasticidin and ampicillin resistance (Invitrogen) 
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pOG44 eukaryotic constitutive expression vector of FLP recombinase, with 
ampicillin resistance (Invitrogen)  
 
 
U6/STAT3 RNAi eukaryotic constitutive expression vector of RNAi pairs, with 
ampicillin resistance; the plasmid expressing the STAT3 siRNA pair: 
5'AgUCAggUUgCUggUCAAAdTdT3' and 5'UUUgACCAgCAACCUgACUdTdT3'; kind 
gift from Ralph Buettner  
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4.3.2 Baculoviruses 
 
Viruses expressing full length human STAT3 were generated by Dr. Uwe Hoffmann. 
 
Viruses expressing c-src were a kind gift from James Turkson, and are described in 
(Zhang et al. 2000). 
 
4.4 Cell culture 
4.4.1  Mammalian cell lines 
 
All mammalian cells were maintained in a Hereaus 6000 incubator, in a water-
saturated atmosphere at 37°C and under 5% CO2. The cells were maintained in 
flasks with filter tops, or in 10 cm dishes. When confluent, they were washed with 
PBS, and treated for approx. 15 min at 37°C with trypsin-EDTA (Invitrogen). When 
detached, they were replated at 1:10 dilutions or higher. If lower dilutions were 
required, cells were first centrifuged for 5 min at 150 g, then resuspended and plated 
in fresh medium. 
Serum was always heat inactivated prior to use (20 min at 56°C), in order to 
inactivate the complement. All media were stored at 4°C and preheated for 15 min at 
37°C before dispensing to the cells. 
Cell stocks were frozen at 1x106 cells/ml in regular culture medium supplemented 
with 8% DMSO. Cells were kept at  80°C for at least 24 h, before storage in liquid 
nitrogen. 
PBS    0.2 M NaCl 
2.5 mM KCl 
8 mM Na2 hPO4 
1.5 mM KH2PO4 
pH 7.4 
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Cell lines 
 
NIH3T3 Immortalized mouse fibroblasts; ATCC cell line CRL-
1658. These cells are cultivated in DMEM supplemented 
with 10% FBS. 
NIH3T3-vSrc-TKS3 Mouse fibroblasts (NIH3T3 cells) transformed by the 
stable expression of v-Src. They have stable incorporation 
of the STAT3 reporter construct pLucTKS3 (Turkson et al. 
1999). These cells are cultivated in DMEM supplemented 
with 10% FBS and 500 µg/ml Neomycin. 
293Trex Human epithelial kidney cells transformed with adenovirus 
5 DNA derived from the ATCC cell line CRL-1573. They 
have stable incorporation of the pFRT/LacZeo and 
pcDNA6/TR plasmids. They are designed to generate 
stable cell lines containing the inducible plasmid 
pcDNA5FRT/FRT/TO, which can be incorporated into the 
genome through recombination. These cells are cultivated 
in DMEM supplemented with 10% FBS,                      
2 mM L-Glutamine, 100 µg/ml zeocin, and 15 µg/ml 
blasticidin. When the cells have incorporated 
pcDNA5FRT/FRT/TO, the zeocin selection has to be 
stopped and replaced with 100 µg/ml hygromicin. 
Charcoal treated FBS was used (Biowest, S175F) for 
these cells in order to avoid the presence of tetracycline in 
the serum. 
MCF10A Human immortalized breast epithelial cell line; ATCC cell 
line CRL-10317. These cells are cultivated in 
DMEM/Ham12 supplemented with 10% Horse Serum, 
2 mM L-Glutamine, 20 ng/ml EGF, 100 ng/ml 
Choleratoxin, and 500 ng/ml Hydrocortison.  
DU 145 Metastasized human epithelial prostate cells; ATCC 
number HTB-81. These cells are cultivated in MEM alpha 
supplemented with ribonuleosides and 
deoxiribonucleosides, 10% FBS, and 2 mM L-glutamine. 
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4.4.1.1  Mycoplasma analysis 
 
While a cell-line was kept in culture, every three months, cells were tested for 
mycoplasma infection. Since antibiotics inhibit the PCR reaction, they were removed 
from the culture medium two weeks before the mycoplasma analysis. 5000 cells were 
resuspended in 1 ml medium (better than PBS, to allow detection of contamination in 
the medium), and centrifugation at 12000 g for 20 min. The pellet was resuspended 
in water, and after a second centrifugation (20 min, 12000 g) the cells were 
resuspended in 20 µl water and lysed at 99°C for 10 min. The lysate was then 
spinned down shortly, and 2.5 µl of the suspension was used for the PCR reaction. 
The mycoplasma detection was done according the protocol of the VenorGeM-QP kit 
(Minerva Biolabs). The real time PCR reaction was performed in a Roche Light 
Cycler. 
 
4.4.1.2  Expression of proteins in mammalian cells 
 
4.4.1.2.1 Transfection of NIH3T3, 293Trex, and DU145 cells 
 
All these cells were transfected by lipofection, using the Lipofectamine 2000 reagent 
(Invitrogen). The day before transfection, 4x105 cells/well were seeded onto a 6 well 
plate. The next morning, 10 µl Lipofectamine 2000 were mixed with 250 µl Optimem 
(Invitrogen) in an Eppendorf tube, and 4 µl DNA with other 250 µl Optimem in 
another tube. Both solutions were incubated for 15 min at RT. Then, they were mixed 
and incubated for 15 min RT. During this incubation, the medium was replaced with 
2 ml medium without serum. 750 µl medium without serum were added to the 
transfection solution, and mixed carefully. Finally, the medium was removed from the 
cells and 1 ml transfection solution was dispensed to the cells, and then incubated at 
37°C. 6 h later, the transfection medium was replaced with 2 ml medium with serum, 
in order to minimize toxicity. 24 h after transfection, selection medium was added. 
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4.4.1.2.2 Transfection of MCF10A  
 
These cells were transfected by lipofection, using the Effectene transfection reagent 
(Qiagen). The day before transfection, 4x105 cells/well were seeded onto a 6 well 
plate. The next morning, cells were washed with PBS and 1.6 ml full medium 
dispensed. 4 µg of DNA were diluted in EC Buffer (100 µl total volume), 8 µl 
enhancer were added and mixed by vortexing for 1 sec. The mixture was incubated 
at RT for 2-5 min, and spinned down. 25 µl Effectene transfection were dispensed 
and mixed by pipetting up and down 5 times, and incubated at RT 5-10 min. 600 µl 
full medium were added, mixed again by pipetting up and down twice, and dispensed 
dropwise onto the cells, while the plate was gently swirled. 24 h later, selection was 
started. 
 
4.4.1.2.3 Generation of stable cell lines  
 
In order to determine the antibiotic concentration to be applied for selection, each cell 
line was tested separately. Untransfected cells were plated on 6-well plates, so as to 
have them at approx. 90% confluency. The following day, a range of antibiotic 
concentrations (specific for each antibiotic) was added to the cells, and the 
percentage of dead cells was monitored over the next two weeks. The concentration 
chosen for selection was such that it caused the death of >80% of the cells within the 
first week, and >95% after the second week. An appropriate concentration should not 
kill all cells within 48 h. 
Puromycin   Tested concentrations: 1, 2.5, 5, 7.5, 10 µg/ml.  
MCF10A: 1 µg/ml 
Zeocin   Tested concentrations: 50, 125, 250, 500, 750, 1000 µg/ml 
DU145: 500 µg/ml  
MCF10A: 500 µg/ml 
MCF10A v-src Puro B3: 500 mg/ml 
293FlipIn: 100 mg/ml 
Blasticidin   Tested concentrations: 0.5, 1, 2.5, 5, 7.5, 10 µg/ml 
DU145: 2.5 µg/ml  
MCF10A: 5 µg/ml 
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MCF10A v-src Puro B3: 5 µg/ml 
293FlipIn: 15 µg/ml 
Hygromicin  Tested concentrations: 10, 50, 100, 200, 400, 600 µg/ml 
DU145: 100 µg/ml 
MCF10A: 10 µg/ml 
MCF10A v-src B3: 10 µg/ml 
293Trex: 100 µg/ml hygromicin 
24 h after transfection with a specific plasmid, the required antibiotic was added at 
the established concentrations. Cells were monitored over the following weeks. Once 
large clones had appeared (should be visible with the bare eye around the third or 
forth week), they were picked up with a pipette tip and transferred to a 96-well plate. 
The clones were expanded and passed into 24, 12, and then 6 well plates. As soon 
as cells were available in sufficient number, they were screened for expression of the 
desired protein, while they were expanded to prepare a stock of the cell line. 
 
4.4.1.2.4 Inducible expression of transgenes in mammalian cells  
 
4.4.1.2.4.1 Ecdysone system 
 
The ecdysone-inducible mammalian expression system is based on the molting 
induction system of Drosophila, but has been modified for inducible expression in 
mammalian cells. The system uses the steroid hormone ecdysone analogs, 
ponasterone A or muristone A, to activate expression of the gene of interest via 
activation of a heterodimeric nuclear receptor. With this system the protein 
expression can be induced more than 200-fold.  
The gene of interest, STAT3β, was cloned into the inducible expression plasmid, 
which contains 5 modified ecdysone response elements (E/GREs) upstream of a 
minimal heat shock promoter and the multiple cloning site (pIND-TOPO-TA vector). 
Cloning was done by TOPO cloning (Invitrogen). 
Along with the inducible plasmid, pVgRXR, a vector expressing the ecdysone 
receptor subunits, was transfected into the cells. After generation of stable cells, the 
expression of the gene was induced with 5 µM ponasterone or 10 µM muristone for 
at least 24 h, and the expression of STAT3β was tested by Western blotting. 
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4.4.1.2.4.2 Tetracycline system 
 
The Flip-In T-Rex system was used for the generation of stable mammalian cells 
exhibiting tetracycline-inducible expression of STAT3β from a specific genomic 
location. To generate these cells, first, independent integration of a plasmid 
expressing the Tet repressor (pcDNA6/TR) and of a plasmid containing a Flip-
recombination target (FRT) site (pFRT/LacZeo) into the genome of the mammalian 
cell line of choice was required. After cloning and screening of the clones for the 
LacZ reporter gene expression (see below) to identify clones with integration of the 
pFRT/LacZeo plasmid into a high-expression region of the genome, STAT3β was 
introduced into this site, by cotransfection of the pcDNA5FRT/FRT/STAT3β vector 
with plasmid pOG44. 
50 hours after transfection, cells were selected with 15 µl/ml blasticidin and 100 µg/ml 
hygromicin. One sufficient cells available, they were tested by Western blotting for 
induction of STAT3β after treatment with 1 µg/ml tetracycline.  
 
4.4.1.2.4.3 Confirmation of gene incorporation and protein expression 
 
In order to verify the incorporation of the plasmid, reporter assays were performed 
when applicable. Otherwise, whole cell extracts prepared for each clone, and the 
expression of the desired protein was analyzed by Western blotting. 
 
4.4.1.3 β-Galactosidase in situ staining 
 
Cells were washed once with PBS before adding 2 ml fixing solution, and incubated 
at RT for 15 min. They were then washed twice with PBS, and 1 ml of X-Gal solution 
was added. Cells were incubated between 15 min and 24 h at 37°C in the incubator. 
The time of incubation was adjusted depending on the intensity of the blue staining. 
Cells were then washed twice with PBS, and photographed under the microscope 
(DMIL Leica), and images were captured using a digital camera (DC 300F, Leica). 
Fixing solution  0.25% v/v glutaraldehyde in PBS 
Staining solution  A 2% stock solution of X-Gal (Invitrogen) was prepared in 
dimethyl formamide (DMF). This was then diluted to 
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0.02% in a solution of 2 mM MgCl2, 5 mM K4Fe(CN)6.3 
h2O, and 5 mM K3Fe3(CN)6 in PBS. 
 
4.4.1.4 Whole cell lysates 
 
Cells were washed with PBS, and 200 to 300 µl RIPA buffer were added to each     
6-well dish (or 1 ml for a 10 cm dish). They were then scraped and transferred to an 
Eppendorf tube. The tubes were rotated at 4°C for 30 to 45 min in a rotating wheel. 
Finally, they were centrifuged at 14000 rpm and 4°C for 10 min, after which the 
supernatant, containing the whole cell lysate, was transferred to a new tube. 
RIPA     20 mM Hepes pH 7.4 
150 mM NaCl 
5 mM EDTA 
1% NP40 or Triton X 100 
2.5% Deoxycholate 
0.1% SDS  
Fresh: 1:500 of protease inhibitor cocktail set III (Calbiochem) 
1 mM sodium orthovanadate 
1 mM DTT 
 
4.4.1.5 Nuclear cell extracts 
 
Cells were placed on ice and washed twice with cold PBS/vanadate. 1 ml 
PBS/vanadate was added per 10 cm dish, and cells were scraped from the plate. The 
cells were pipetted into an Eppendorf tube and centrifuged for 5 min at 220 g. All 
centrifugations were done at 4°C. The cellular pellet was resuspended in twice its 
volume of Buffer A, and centrifuged for 5 min at 220 g. The supernatant was pipetted 
into another Eppendorf tube and kept as cytosolic extract, and the pellet was 
resuspended in once its volume of Buffer C, and incubated on ice for 30 to 45 min. 
Insoluble material was removed by centrifugation at 15000 g for 20 min. Protein 
concentrations were determined by the BCA method and extracts were stored at - 80 
°C until use. 
PBS/Vanadate   0.2 M NaCl 
2.5 mM KCl 
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8 mM Na2 hPO4 
1.5 mM KH2PO4 pH 7.4 
     100 µM Na3VO4 
Buffer A    10 mM Hepes-KOH pH 7.8  
1.5 mM MgCl2 
10 mM KCl 
0.5 mM DTT 
0.2 mM PMST 
1 mM Na3VO4 
Buffer C    20 mM Hepes-KOH pH 7.8  
1.5 mM MgCl2 
420 mM NaCl 
0.2 mM EDTA 
0.2% v/v glycerol 
0.5 mM DTT 
0.2 mM PMSF 
1 mM Na3VO4 
 
4.4.1.6  Immunofluorescent staining 
 
Cells were seeded on glass slides and incubated with the biotinylated and cell-
permeable peptides. 1 h later, slides were fixed in 4% paraformaldehyde for 20 min, 
permeabilized in 0.2% Triton 100-fold for 5 min, blocked with 5% FBS for 30 min and 
incubated with a 1:200 dilution of FITC conjugated streptavidin (Jackson 
ImmunoResearch) for 45 min at RT in the dark. Staining was visualized using a 
fluorescence microscope (DM LB, Leica), and images were captured using a digital 
camera (DC 300F, Leica). 
 
4.4.1.7  Proliferation analysis 
  
Cells were plated on a 96-well plate and treated as required. Upon treatment, 5 µl of 
the oxidized form AlamarBlue were added to 100 µl culture medium. The reduced 
form of AlamarBlue was measured by fluorescence (excitation λ 560 nm, emission λ 
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590 nm) during the following 1 to 6 h with a Spectra Magemini fluorescence reader 
(Molecular Devices). 
 
4.4.1.8 Apoptosis analysis 
 
Caspase activation assay: MCF10A cells were seeded in 50 µl on a 384-well plate 
and several hours later, when attached, starved overnight. The next morning medium 
was changed and EGF was added to the treated group, and 24 h later the 50 µl 
caspase substrate (Asp-Glu-Val-Asp-Rhodamine) dilution to all cells. 3 hours later, 
the product (rhodamine) was measured by fluorescence (excitation λ 499 nm, 
emission λ 521 nm) with a Spectra Magemini fluorescence reader. 
 
4.4.1.9  Colony formation in soft agar 
 
A 3% agar (Difco agar noble, BD Bacto Agar, or Biozym Seaplaque agarose) stock 
solution was prepared in PBS. The solution was autoclaved in a microwave (boiled 3 
times), and when clear and well dissolved, it was maintained at 48°C in a water bath, 
along with the culture medium. The agarose was diluted in the medium, and a 1% 
agar solution was plated on the wells (1.5 ml/well for 6-well plates). While this 
underlayer solidified, cells were counted, and 6000 cells were mixed in 1.5 ml 0.5% 
agar prepared in culture medium. Cells were incubated for 2 h at 37°C to allow for 
cells to settle down, and the plates were then incubated at RT to allow for 
solidification of the agar. Once the agar was solid, 500 µl medium were added to 
each well, and cells were placed into the incubator (37°C, 5% CO2). The medium was 
changed every three to four days. 14 days later, colonies were stained with 
iodonitrotetrazoliumchlorid.  
Staining solution:   100 mg iodonitrotetrazoliumchlorid  
25 ml water  
25 ml methanol 
 
4.4.1.10 Tumor xenografts 
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Female, inbred SCID mice were purchased at Charles River (Cb-17/lcr/Crl-scidBR). 
These mice present a severe combined immunodeficiency affecting both B and T 
lymphocytes. They have normal NK cells, macrophages, and granulocytes. 
These mice were kept at 25°C in an incubator with filtered air. Food (standard diet for 
mouse and rats, Altromin) and sterile water were always available for the animals.  
Cells were cultured in the usual conditions, trypsinized, and washed twice in PBS. 
They were counted as described below and 5x106 cells were resuspended in 100 µl 
PBS with Mg+ 2 and Ca+ 2 (Biochrom) and the suspension injected subcutaneously 
into the back of the mice. Six mice of 10 weeks of age, weighing 17 to 20 mg were 
used for each cell line. At the time of injection, the viability of the cells was controlled 
as described below. No more than 10% should be dead. After injection of the cells, 
the weight of the animals and the growth of the protrusion at the site of injection were 
monitored every third day.  
 
4.4.2 Prokaryotic cells  
 
All bacterial stocks were stored at - 80°C. 
 
E.Coli One Shot TOP10 (Invitrogen)  
Chemically competent. Used for chemical transformations: 
Cells were thawed on ice, and 20 µl were aliquoted into a sterile Eppendorf tube. 
Approx. 1 µg DNA was added and mixed by gentle flicking of the tube. The mixture 
was incubated on ice for 15 min, then at 42°C for 30 s, to heat shock the cells. 500 µl 
of SOCS medium were added to the cells, transferred to a sterile 14 ml 
polypropylene (PP) filter top tube and incubated at 37 °C and 200 rpm for 1 h. The 
bacteria were then distributed onto an agar plate containing the right antibiotic 
(usually ampicillin, which is applied at 100 µg ampicillin/ml LB-agar). If antibiotic had 
not been added while preparing the agar plates, it was added before plating the 
transformed cells, adding the required antibiotic for 20 ml LB medium, and 
distributing well with the digralski spatula. The plates were then incubated O/N at 
37°C. 
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LB medium  10 g/L tryptone or peptone  
5 g/L yeast extract  
5.14 g/L NaCl (88 mM final) 
All the components were dissolved in water and mixed in a 
bucket. When dissolved, the whole volume was distributed in 
500 ml bottles, and autoclaved for 20 min at 121°C (the solution 
was not left to incubate overnight prior to autoclavation, since 
potential contaminants could expand in the broth). Prior to being 
added to the cells it was cooled down to room temperature. 
Agar plates  15 g/L agar (1.5% w/v final) were added to a 1 L to a bottle, then 
1 L of the non-sterilized LB solution, prepared as described 
above, was added to the bottle. The mixture was autoclaved 
immediately (20 min at 121°C), and while still warm and liquid, 
approx. 20 ml of the solution was distributed to each 10 cm dish. 
The dishes were placed on a flat surface, while the agar plates 
cooled down to room temperature and solidified. When solid, 
they were stored at 4°C and wrapped in plastic to keep in the 
humidity. 
 
E.Coli DH10B Eletctromax (Invitrogen)  
Used for electrotransformation:  
The electrocuvettes were placed for 15 min on ice, and the S.O.C. medium 
(Invitrogen) was prewarmed at 37°C. The bacteria were thawed on ice, and the 
electroporator (Bio-Rad E.Coli Electroporator) was set to 2.5 kV. 1-5 µl plasmid DNA 
(1 µg or less), and 20-30 µl bacteria were pipetted into the electrocuvette and mixed 
with the tip of a Pasteur pipet, placing the mixture at the bottom of the cuvette. The 
samples were electroporated. The optimal pulse time should be of approx. 5 ms. If 
electric pulse was appropriate, 500 µl SOC medium were added to the treated 
bacteria, and mixed carefully. The solution was transferred into a 14 ml 
polypropylene (PP) filter top tube, and incubated for 1 h at 200 rpm and 37°C. The 
cells were then plated on agar plates and incubated O/N at 37°C . 
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E. coli DH10Bac (Invitrogen) 
Chemically competent bacteria carrying a baculovirus shuttle vector bMON14272 
(bacmid; contains the attachment site for the bacterial transposon, Tn7, i.e. mini-
attTn7), and the helper plasmid pMON7124 (encodes the transposase). This allows 
the preparation of recombinant bacmids by transposition between the shuttle and the 
pDest10 vectors. These cells were transformed by chemical trasformation as 
described for E.Coli One Shot TOP10, and were used for the generation of human 
STAT3 recombinant bacmids .  
 
4.4.2.1 Bacterial culture 
 
The bacteria were picked from the agar plates with a pipet tip, and placed in 2.5 ml 
LB-Medium with the required antibiotic. They were incubated at 37°C under 200 rpm 
for 1 h, and then diluted 1:500 to 1:1000 in LB-Medium with antibiotic. The incubation 
was continued O/N. The following morning, 800 µl of the LB culture were 
supplemented with 200 µl of sterilized glycerol 100%, and this bacterial stock was 
stored for approx. 2 years at - 20°C, and for longer periods at - 80°C. The rest of the 
culture was used for the extraction of DNA. 
 
4.4.2.2  Preparation of plasmid DNA 
 
The plasmids were purified according to the QIAGEN Plasmid Mini-, Midi, and Maxi 
Kits. 
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4.4.3 Insect cells  
 
These cells were used for the preparation of viral stocks and the production of 
proteins. All insect cells were cultivated at 27°C under atmospheric CO2 conditions, 
and grown in adherent and in suspension cultures. 
 
Sf9 cells Sf9 cells are derived from Spodoptera frugiperda. They were 
cultivated in 1 L Sf-900 II SFM (Invitrogen) supplement 
50 U Penicillin/ 50 µg Streptomycin (Invitrogen). The cells were 
always maintained in the serum-free medium. To store cells, 
1x107 cells/ml were frozen in a mixture of 60% Graces Insect 
Medium, 30% FBS, and 10% DMSO. 
Hi5 cells High Five cells from Tirchoplusia ni flies. High Five cells are 
characterized by a higher expression of recombinant proteins 
than other insect cells. They were cultivated in 1 L Express five 
SFM (Invitrogen) supplemented with 10 ml L-Glutamine 200 mM 
(Invitrogen). To store cells, 1x107 cells/ml were frozen in a 
mixture of 42.5% conditioned Express Five SFM, 42.5% fresh 
Express Five SFM, 10% DMSO, and 5% FBS. 
 
4.4.3.1  Production of proteins in insect cells 
 
4.4.3.1.1  Suspension culture of Sf9 and Hi5 cells 
 
In order to assess the cell number, 10 µl of the culture were taken and mixed with 10 
µl 0.4% trypanblue (Sigma). 10 µl were placed onto a Neubauer chamber, and both 
the top and bottom corners (each corner contains 16 squares) were counted (Fig.5). 
Blue (dead) and white (alive) cells were counted separately. The mean of the four 
corners was calculated, and the number of cells was calculated by:  
Cells/ml= mean cell number x 104 x 2 
Viability (%)= number of living cells x 100/total cell number 
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Fig.5. Magnified picture of a Neubauer Chamber. 
 
If the viability of the cells was >90%, cells were adjusted to 4 to 5x105 cells/ml with 
fresh medium, and seeded into a spinning flask (TECHNE/ThermoDUX). They were 
incubated at 27°C on a cell culture stirrer with 85 rpm spinning 
(TECHNE/MCS104L4) until they reached 2 to 3x106 viable cells (duplication time 18 
to 24 h). Every three weeks, cells were pelleted at 100 g for 5 min in order to remove 
cellular waste and debris. 
 
4.4.3.1.2 Preparation of viral stocks 
 
Viruses were prepared in SF9 cells. 9x105 cells/well were seeded in 2 ml Sf900II 
medium with 1000 U/ml penicillin and 100 µg/ml streptomycin on a 6-well plate 
(Costar). The plate was placed in a humidifying chamber (i.e. box with humid paper 
towel), and incubated for 1 h at 27°C in order to allow for cell attachment. For 
transfection, 5 µl bacmid-miniprep were added to 100 µl Sf900II medium without 
antibiotics. In another tube, 6 µl Cellfectin (Invitrogen) were mixed with 100 µl Sf900II 
medium without antibiotics. Both solutions were mixed and incubated for 30 min at 
RT. 800 µl Sf900II Medium were prepared in a 5 ml polystyrene tube. Cells were 
washed with 2 ml antibiotic-free medium, and the Cellfectin/DNA mixture was gently 
mixed with the 800 µl medium. The medium was removed from the cells and 
replaced with the transfection mixture (1 ml). The plates were incubated for 5 h at 
27°C in a humidifying chamber. Medium was then removed, and 2 ml Sf900II with 
1000 U/ml penicillin and 100 µg/ml streptomycin added. Cells were incubated at 
27°C, and 96 h later, the culture medium was taken and centrifuged for 5 min at 
500 g. The supernatant was placed in polypropylene tubes (viral stocks P1), and 
stocked at 4°C in the dark. 
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4.4.3.1.3  Virus amplification 
 
In order to increase the amount and titer of the viral stock, it was amplified in a 
suspension culture of Sf9 cells. 1 ml of virus P1 was added to 10 ml of a 1.5 to 
2.0x106 viable cells/ml, and incubated for 96 h at 27°C and approximately 100 rpm . 
The viral supernatant (virus P2) was harvested as described before under 
preparation of viral stocks. 5 ml of virus P2 were inoculated into 50 ml of a 1.5 to 
2.0x106 cells/ml culture, and virus P3 harvested after 96 h. 
 
4.4.3.1.4 Plaque assay 
 
Sf9 cells or Hi5 cells were counted as described before. They were adjusted to a 
concentration of 0.5x 106 cells/ml with fresh Sf-900 II SFM with 50 U/L penicillin and 
50 µl/L Streptomycin, and 2 ml/well were placed onto a 6 well plate. Cells were 
incubated for 1 h at 27°C in a humidifying chamber. Viral dilutions (10-2 to 10-8) were 
prepared in Sf-900 II SFM with 50 U/L penicillin and 50 µg/L streptomycin (e.g. 50 µl 
stock P3 into 5 ml medium). Usually the virus titer lied between 10-6 to 10-8. Under 
these circumstances, it was sufficient to infect cells with the 10-6 to 10-8 dilutions. 
When the cells were attached, the medium was replaced with 1 ml viral dilution and 
the plates were placed in the humidifying chamber wrapped with alumium. They were 
incubated at 27°C shaking at approx. 80 rpm. A 4% agarose gel  (Invitrogen) was 
melted at 70°C in a water bath (approx. 1 h required). In two glass bottles, 15 ml of 
1.3-fold Sf900 medium with 100 U/ml penicillin and 100 µg/ml Streptomycin 
(Invitrogen) were prewarmed at 39°C, and 5 ml of 4% melted agarose were added. 
4 h after the viral infection, the medium was sucked off and 2 ml/well agarose overlay 
were carefully dispensed to each well. The plates were incubated 20 min at RT 
without shaking, and placed in a humidifying chamber for incubation at 27°C. The 
humidity in the chamber was controlled every day, and between 4 to 8 days later, 
when no more plaques appeared, the number of plaques were counted (optimal 
number: 5 to 30 plaques per well) and the virus titer calculated: 
pfu/ml = number of plaques/volume virus/dilution factor  
(e.g 20 plaques at a viral dilution of 10-7, corresponds to a virus titer of 20/1/10-7= 
2 x 10-8 pfu/ml) 
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4.4.3.1.5 Infection kinetic 
 
Cells were counted, and eight separate cultures of Sf9 or Hi5 cells were prepared in 
fresh medium in order to test the 1,2,5, and 10 multiplicity of infection (MOI=pfu/cell), 
each at two different harvesting times (40 and 48 h). 1.5 to 2.0x106 viable cells/ml 
were dispensed either into an Erlenmeyer (Duran/Bender & Hobein 391A0285), or 
into a spinnerflask (TECHNE/ThermoDUX F7608). In order to ensure a good aeration 
of the culture, it should not occupy more than one tenth of the maximal volume in the 
Erlenmeyer, or half of the maximal volume in the flask. The viral inocolum was 
calculated by: 
Inoculum (ml)= (MOI(pfu/cell)x number of cells)/titer of viral stock (pfu/ml) 
The appropriate virus volume was added to each culture, and the culture was 
incubated at 27°C and 100 rpm  agitation. After 40 h or 48 h, cells were centrifuged 
at 600 g for 10 min.  
 
4.4.3.1.6 Insect cell lysates 
 
Cells were washed twice with ice-cold PBS, and precipitated at 600 g and 4°C for 
5 min. An additional washing step with PBS containing 1 mM sodium orthovanadate 
was performed when preparing phosphorylated proteins. Cells were resuspended in 
1% Nonidet P-40 lysis buffer (10 ml buffer for a 50 ml culture) and lysed on ice for 
10 min. The lysate was then centrifuged at 14000 g, 20 min, 4 C. The supernatant 
was either immediately used, or stored in 500 µl aliquots at - 80°C. 
1% Nonidet P-40 lysis buffer  50 mM HEPES (pH 7.9)  
150 mM NaCl,  
1% Nonidet P-401 
water  
Fresh:     Complete Mini protease inhibitor tablets (Roche) 
20 mMNaF 
1 mM sodium orthovanadate 
1 mM DTT 
STAT3 expression was assessed by Western blotting, as described before. 
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4.4.3.1.7 Protein expression 
 
The protein expression was performed in suspension culture of either Sf9 or Hi5 
cells. The optimal conditions for infection were deduced from the kinetic studies, and 
scaled up proportionally. The expression of the protein was verified by Western 
blotting, as described below. 
4.5 In vitro assays 
 
4.5.1  Protein analysis 
 
4.5.1.1 Protein quantification 
 
The determination of the protein concentration was done in 96-well plates, (Greiner) 
using the bicinchoninic acid (BCA) method (Pierce). A standard curve of BSA (1000, 
800, 700, 600, 500, 400, 200, 0 µg/ml) was prepared in PBS, supplemented with the 
same amounts of lysis buffer present in the wells with the samples (1 µl per well). 1 µl 
of each sample was diluted in 9 µl PBS, and 200 µl of the BCA solution was added to 
all wells. The plate was incubated for 30 min at 37°C. The absorbance was 
measured at 562 nm with a Rainbow microtiter plate reader (SLT), and the protein 
concentration was determined by linear regression.  
 
4.5.1.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Equal amounts of total protein (20 to 60 µg) were prepared, and the volume of all 
samples was adjusted with PBS, to a maximal volume of approx. 60 µl (resp 30 µl) in 
the case of an 18-well (resp 26-well) gel. Each sample was supplemented with 4-fold 
XT Sample Buffer (Bio-Rad), and 20-fold XT Reducing Agent (Bio-Rad). The samples 
were then boiled for 5 min at 95°C in a heating block. The gels (Criterion XT Bis-tris 
10% or 4 to 12% polyacrylamide gels, Bio-Rad) were assembled in the running 
chamber, and covered with 1-fold XT MOPS running buffer (Bio-Rad). 10 µl 
molecular weight ladder (Benchmark Invitrogen) and the boiled samples were loaded. 
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The samples were run at 100-150 V, and the gel was stopped when the dye front 
arrived at the bottom of the gel.  
 
4.5.1.3 Western blotting   
 
The proteins on the SDS-PAGE gel were transferred onto a 0.2 µm nitrocellulose 
membrane with the transfer unit (Criterion blotter, Bio-Rad) covered with 1-fold 
transfer buffer. To avoid overheating the solution, a frozen ice pack was kept inside 
the buffer. The transfer was performed for 30 min (at most 1 h) at 100 V. The transfer 
of the proteins to the membrane was checked with PonceauS red staining, and then 
washed with water. Next, the membrane was blocked with 20 ml blocking solution for 
1 h at RT under 100 rpm shaking (alternatively O/N at 4°C with gentle shaking). Then 
it was washed three times for 3 min with PBST under shaking, and incubated with 
20 ml primary antibody solution. All antibody incubations were done for 1 h at RT 
under 100 rpm shaking (alternatively at 4°C O/N with gentle shaking). After washing 
four times with PBST, it was treated with 20 ml of secondary antibody, and washed 
again six times with PBST. Finally, the membranes were incubated for 5 min with the 
ECL (Enhanced Chemiluminescence) solution and exposed to Hyperfilm ECL 
chemiluminescence films (Amersham Biosciences).  
 
Running buffer 10-fold XT MOPS running buffer (Bio-Rad) diluted in water 
Ponceau red  1.25 g Ponceau S 
   52 ml sodium acetate 96% 
448 ml water 
Transfer buffer 100 ml 10-fold transfer buffer (i.e. 22.3 g Tris, 120.1 g glycin, up 
to 1 L water) 
200 ml methanol  
700 ml water 
20-fold TBS:   3 M NaCl 
   1 M Tris  
pH was adjusted to 7.5 with concentrated HCl 
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TBST    250 ml 20- TBS 
12.5 ml 20% tween 
up to 5 L water 
TBST   24.2 g Tris 
   80 g NaCl 
  up to 1 L water 
3/4 of the solution were adjusted to a pH of 7.6 with HCl, and the 
volume was finally adjusted with water 
Blocking solution:  5% non-fat milk powder 
   1000 ml PBST 
1ary antibody  5% BSA  
   1 mM NaN2 (only when reusing solution) 
   TBST 
2ary antibody 1:2000 antibody 
5% (w/v) non-fat milk powder 
TBST 
 
4.5.1.4 Electrophoretic mobility shift assay (EMSA)  
 
Labeling of radioactive probe: 
STAT proteins can bind to the synthetic sis-inducible element (SIE) isolated from the 
human c-fos promoter. The m67 SIE variant contains a mutation that allows for 
binding of STAT1 and STAT3 with equal affinity. The radioactive labeling of the 
double stranded probe was done by addition of [32P]α-dATP to the 5ends with the 
Klenow enzyme. Free nucleotides were removed by the Quiaquick Nucleotide 
Removal kit (Qiagen). The incorporated radioactivity was then measured in a β-
counter . 
m67SIE: 5-GATTGACGGGAACTG-3 (STAT binding sequence underlined) 
EMSA: 
Nuclear extracts (5 µg), containing 0.14 µg/µl poly-(dI-dC) and 32P-labeled double 
stranded DNA probe were incubated for 20 min on ice. For super-shift assays, the 
indicated antibody was added, in the other samples the volume was adjusted with 
water. Samples were electrophoresed in 5% polyacrylamide gel in 0.25% Tris-borate-
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EDTA buffer. Gel-shift grade anti-mouse STAT1 and STAT3 (Santa Cruz) polyclonal 
antibodies were used for supershifts. 
 
4.5.1.5 Enzyme coupled immunosorbent assays (ELISA) 
 
The signal obtained in these assays was measured in the Rainbow microtiter plate 
reader (SLT). 
 
4.5.1.6  STAT3 DNA-binding ELISA  
This assay was performed as described in the TransAM kits for STAT proteins 
(Active Motive). 
 
4.5.1.7  Dimerization ELISA 
 
4.5.1.7.1 Streptavidin based ELISA 
 
Coating of plates: 
Different amounts of biotinylated peptide (AAPY*LKTKFK-biotin and PY*LKTKK-
biotin; FKTKLYPAAK-biotin as negative control) were dispensed on streptavidin-
coated 96-well plates and incubated at room temperature for 30 min under 100 rpm 
shaking. Plates were washed four times, and incubated with 10 µg/ml anti-phospho-
STAT3 antibody. After one hour incubation at room temperature under 100 rpm 
shaking, plates were washed three times, and incubated with 1 µg/ml HRP-
conjugated anti-rabbit antibody. Signal was developed using ABTS reagent and 
measured at 405 nm. 
 
Complete assay: 
Biotinylated-phospho-STAT3-specific peptides were dispensed on streptavidin-
coated 96-well plates and incubated at room temperature for 30 min under 100 rpm 
shaking. Plates were washed four times, and incubated with Sf9 cell lysates. Upon 
1 h incubation with 10 µg/ml anti-STAT3 antibody at RT under 100 rpm shaking, 
plates were washed 3 times, and incubated with 1 µg/ml HRP-conjugated anti-rabbit 
antibody. Signal was developed using ABTS reagent and measured at 405 nm. 
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4.5.1.7.2 Flag-tag based ELISA  
 
A 5 µg/ml anti-flag-antibody solution was prepared in carbonate buffer pH 8.4. 100 µl 
were dispensed onto a Maxisorb plate (Nunc), and the lids of the plate were sealed 
with parafilm in order to avoid evaporation. The plates were incubated at 4°C 
overnight. The following morning, plates were washed four times with PBST, and 
blocked with 5% BSA in PBST for 1 h at 100 rpm on a rocking shaker. All the shaking 
was performed at this speed, and from this step on, the assay was performed at RT. 
In the mean time, 15 µl of non-phosphorylated Sf9-STAT3 cell lysates were either 
incubated with Flag-tagged peptides (Y*LKTKFGGGGGGDYKDDDDK or 
KFPYKTLGGGGGGDYKDDDDK as control) on a 96-well plate with v-shaped 
bottom, and rocked for 30 min. The concentration of peptide was calculated at the 
final assay volume, which was 100 µl. Flag-tagged peptides were added (30 min at 
RT and 100 rpm  shaking), and, after this incubation, the assay volume was adjusted 
with water to 100 µl in each well, and then bound to the antibody coated plates (1 h, 
RT and 100 rpm shaking). Incubation of STAT3 antibody (1 h, RT and 100 rpm  
agitation) and secondary antibody (1 h, RT and 100 rpm agitation) was done next. 
Finally, ABTS substrate was added to all wells, and the absorbance measured at 
405 nm. 
Competition assay: 
The assay was done as described above, except that the Sf9-STAT3 cell lysates 
were preincubated with the compounds in v-shaped 96-well plates for 30 min prior to 
adding the Flag-tagged peptides. The concentration of the molecules was calculated 
for the final assay volume, which was 100 µl. In order to minimize the DMSO 
concentration in the assay, the compounds were prepared as follows: The 
compounds were dissolved in DMSO at 50 mM. A 7.5 mM dilution of the compound 
was prepared in Tris-buffer (pH 7.5) 2 µL of this solution were added to the cell 
lysates 
PBST     0.2 M NaCl 
2.5 mM KCl 
8 mM Na2 hPO4 
1.5 mM KH2PO4 pH 7.4 
0.05% Tween 20 in PBS 
Tris-buffer   25 mM Tris in water 
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Carbonate buffer pH 8.4 0.1 M NaHCO3 in water 
Set pH to 8.4 with 1 M NaOH  
4.5.2  DNA analysis 
 
4.5.2.1 Determination of DNA concentration 
 
The DNA content was calculated by measuring the absorbance at 260 nm 
(Pharmacia Biotech, Gene Quant). 1 µl of the sample was diluted into 99 µl water, 
mixed well by vortexing, and pipetted into a quartz cuvette (Perkin Elmer, UV/Vis 
spectroscopy cell). One unit of absorbance at this wavelength equals 50 µg of 
double-stranded DNA/mL. 
 
4.5.2.2  Determination of DNA quality 
 
4.5.2.2.1  OD260:OD280  
 
In order to assess the purity of the DNA solutions, the absorbance was measured at 
a wavelength of λ1=260 nm and λ2=280 nm, to measure the DNA and protein 
concentration, respectively. 1 µl of the DNA sample was diluted into 99 µl deionised 
water, mixed well by vortexing, and pipetted into a quartz cuvette. The ratio between 
the absorbances (λ1/λ2) was calculated. The DNA purity was considered of good 
quality with values between 1.6 and 2. Ratios >2 (resp <1.6) indicate a high salt 
concentration (resp contamination by proteins). 
 
4.5.2.2.2   Electrophoretic separation of DNA:TAE gel electrophoresis 
 
Agarose gels of 1.5% agarose (0.9 g Agarose, 60 ml TAE 1X buffer, and 0.5 µg/ml 
ethidium bromide, for a 7 well gel) were prepared to separate DNA fragments of 
around 2000 bp. For very small or much larger fragments the concentration of 
agarose was adjusted. The solution was boiled three times in the microwave and 
mixed well before being poured into the gel caster in order to enssure that the 
agarose was well dissolved. The DNA samples were diluted with 6-fold DNA loading 
buffer and, when the gel solidified, loaded to the gel, along with 10 µl of DNA ladder 
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(New England Biolab). In the case of PCR products, 5 µl out of a total of 50 µl were 
loaded, and in the case of other DNA preparations, approx. 1 µg. The gels were run 
at 100V. 
 
4.5.2.3  DNA purification 
 
Purification of the DNA samples was done when the ratio OD260:OD280 indicated 
impurities, in order to remove the proteins or ions from the DNA solution. 
 
4.5.2.4  DNA precipitation 
 
3 M sodium acetate pH 4.8 to 5.2 was added to the DNA solution at a proportion of 
1/10 of the DNA solution volume, and ethanol 100% at 2.5 times the DNA-volume. 
The solution was well mixed by vortexing, and incubated for 1 h at - 80°C 
(alternatively O/N at -20°C). The mix was then centrifuged at 15000 g for 15 min at 
4°C.  
 
4.5.2.5  DNA isolation from agarose gels 
 
The DNA sample was run by electrophoresis in an agarose gel, as described before. 
The band of interest was cut, and the DNA was isolated according to the QIAGEN 
QIAEXII Gel Extraction Kit. 
 
4.5.2.6  DNA sequencing 
 
To sequence a gene, primers were designed to cover the whole coding sequence at 
intervals of approx. 800 bp. Primer sequences were selected to have a length of 
approximately 20 nucleotides. The G/C content was kept at 50%, and the last residue 
at the 3 end of each primer was a G or C when possible. Sequencing of plasmids 
was done at Sequence Laboratories Göttingen GmbH. Sequence analysis was done 
with the Lasergene software package (DNAStar Incorporation). 
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4.5.2.7  Gene subcloning 
 
4.5.2.7.1 Primer design 
 
In the case of PCR amplifications, two primers were selected, each starting at 
different ends of the gene, and both with opposing orientation, such as to amplify the 
flanked sequence. Primers were designed to have a length of approximately 20 
nucleotides, unless a mutation or a tag was to be introduced, in which case they were 
chosen to be 30 to 50 nucleotides long. The G/C content was kept at 50%, and at 3 
ending with a G or C when possible. The annealing temperature for the primers was 
calculated by  
[4 x (#C + #G) + 2 x (#A + #T)  5]°C 
Primers 
STAT3β clonation: 
Forward: 5ATGGCCCAATGGAATCAGCT3 
Reverse: 5AATTCACATGGGGGAGGTAG3 
STAT3β His-tag clonation: 
Forward: 5ATGGCCCAATGGAATCAGCTAC3 
Reverse: 
5TCAGTGATGGTGATGGTGATGTTATTTCCAAACTGCATCAATGAATC3 
All primers were synthesized at Qiagen. 
 
4.5.2.7.2  PCR protocol 
 
PCR mix:   5 µl 10-fold PCR buffer (Qiagen) 
300 µM dNTP (stock containig10 mM of each dNTP) 
1 µM primer 1 (100 µM stock) 
1 µM primer 2 (100 µM stock) 
2 µl polymerase (Proof Start, Qiagen) 
1 ng to 50 ng plasmid DNA 
water up to 50 µl 
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PCR protocol: 5 min at 95°C (Activation of Proof Start, Qiagen) 
30 s at 94°C (denaturation) 
30 s at 57°C (annealing) 
5 min at 72°C (extension) 
Cycles were repeated 29 times starting at the 
denaturation step. 
30 min at 72°C (extension) 
The PCR protocol was adjusted according to the annealing temperatures of the 
primers used for each amplification. When introducing a tag or a mutation in the 
primers, the protocol was started with 10 cycles at the annealing temperature of the 
primer regardless of the tag, and followed by 20 cycles at the annealing temperature 
of the complete primer. For example, for His-tag introduction into STAT3β:  
  5 min at 95°C (activation of Proof Start, Qiagen) 
30 s at 94°C (denaturation) 
30 s at 62°C (annealing) 
5 min at 72°C (extension) 
Cycles were repeated 10 times starting at the 
denaturation step  
30 s at 94°C (denaturation) 
30 s at 60°C (annealing) 
5 min at 72°C (extension) 
Cycles were repeated 20 times starting at the 
denaturation step with the second annealing temperature. 
30 min at 72°C (extension) 
 
4.5.2.7.3 PCR product purification 
 
The PCR product was purified through isolation from agarose gels, as described 
before. 
 
4.5.2.7.4 Polyadenylation of PCR product  
 
The PCR product was polyadenylated according to the instructions of the QIAGEN A-
Addition Kit. 
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4.5.2.7.5 Topo-TA cloning 
 
4 µl of the PCR product (approx 25 ng) of the polyadenylated DNA product were 
mixed with 1 µl the linearized TopoTA vector, and 1 µl of a 1:5 dilution in water of the 
salt dilution provided with the vector. The mix was incubated at RT for 30 min, and 
transformed into bacteria by electroporation as described before. 
The verification of clonation and orientation of STAT3β into pIND/V5-His-TOPO, and 
STAT3β with his tag into pcDNA5/FRT/TO was done by PCR analysis, using the 
following primers: 
Forward: same forward primer used for the clonation  
Reverse: BGH reverse 5TAGAAGGCACAGTCGAGG3 
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